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 Introduction 
 Cell-based therapies can now be seen in routine med-
ical care and especially for wound management of skin. 
They offer the promise of repairing and/or replacing 
damaged tissue and restoring lost functionality. Several 
cell types and tissues have been proposed as starting ma-
terial for elaborate tissue engineering processing, includ-
ing autologous skin cells, adult stem cells, bone marrow, 
platelets, embryonic stem cells, cadaver skin, acellular 
dermis, de-epidermized dermis, allogenous full-thick-
ness skin substitutes and xenografts  [1–9] . Their clinical 
uses have extended significantly to a wide variety of in-
dications including burns, acute and chronic wounds, 
skin loss, surgical wounds and bullous diseases  [10–13] . 
 One of the major challenges for assuring that more 
patients will benefit from tissue engineering in the future 
is the optimization of the choice of cell type as well as 
their isolation and proliferation. Equally important is the 
delivery system of chosen cells and their interaction with 
scaffolds to create a three-dimensional tissue. Allogenic 
skin products available for therapeutic usage are mostly 
developed with cell culture and foreskin tissue of young 
individuals.
 The dermal fibroblasts from foreskin cells have been 
used in products such as Dermagraft  , TransCyte  and 
ICX-SKN  , and all clinical data show that these products 
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 Abstract 
 Current restrictions for human cell-based therapies have 
been related to technological limitations with regards to cel-
lular proliferation capacity (simple culture conditions), main-
tenance of differentiated phenotype for primary human cell 
culture and transmission of communicable diseases. Cul-
tured primary fetal cells from one organ donation could pos-
sibly meet the exigent and stringent technical aspects for 
development of therapeutic products. Master and working 
cell banks from one fetal organ donation (skin) can be devel-
oped in short periods of time and safety tests can be per-
formed at all stages of cell banking. For therapeutic use, fetal 
cells can be used up to two thirds of their life-span in an out-
scaling process and consistency for several biological prop-
erties includes protein concentration, gene expression and 
biological activity. As it is the intention that banked primary 
fetal cells can profit from the prospected treatment of hun-
dreds of thousands of patients with only one organ dona-
tion, it is imperative to show consistency, tracability and 
safety of the process including donor tissue selection, cell 
banking, cell testing and growth of cells in out-scaling for the 
preparation of whole-cell tissue-engineering products. 
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alone are not capable of full wound closure in a short pe-
riod of time but are predominantly used for wound cov-
erage while waiting for split or mesh grafting  [14, 15] . 
When fetal skin fibroblasts have been used alone in sim-
ilar delivery systems (native collagen), it was shown that 
no other surgical means or grafting techniques were nec-
essary for burns and wounds  [12, 13] . The differences in 
these clinical outcomes could be related to many factors 
and it is most likely the fetal fibroblast itself that is re-
sponsible. Fetal skin cells could offer an ideal solution for 
effective and safe tissue engineering for wounds of all na-
tures.
 Here, we will address important aspects of fetal cell 
therapy including donor selection (only a single organ 
donation necessary), cellular out-scaling (master and 
working cell banks) and defining reproducible processes 
for fetal cell biological bandage production to be used for 
treatments of acute and chronic wounds.
 Quality of Wound Healing in Fetal and Adult Skin 
 Extracellular Matrix Implications 
 Considerable interest and research has been dedicated 
to the understanding of wound healing and the associ-
ated process. Whereas adult cutaneous wounds heal with 
scar formation to restore tissue integrity, fetal skin in ute-
ro is observed to have rapid and scarless tissue repair 
characterized by regeneration of an organized dermis 
with normal appendages and by a relative lack of inflam-
mation  [16–18] . Fetal wound healing and its transition 
from scarless repair to healing with scar formation is sit-
uated at a threshold around 24 weeks of gestation in hu-
mans. The reason for this transition is thus strategic in 
the understanding of specific mechanisms of scarless 
wound healing. 
 Fundamental differences between fetal and adult skin 
as well as the fetal and adult skin wound environment 
may be important in inducing scarfree tissue repair. Ear-
ly in gestation, the dermis is thin, relatively acellular and 
a low extracellular matrix (ECM) is present. During fur-
ther development, dermal collagen is deposited and sul-
fated glycosaminoglycans replace hyaluronic acid among 
other nonsulfated glycosaminoglycans. The extremely 
rapid growth and the loose ECM provide a conducive ter-
ritory for scarless fetal skin repair  [19] . In large animal 
and human models, scarless repair occurs during spe-
cific periods of gestation, from midgestation to the early 
third trimester. There is a transition period between scar-
less and scar-forming repair, scarless healing also de-
pends on the organ involved. In skin, scarless healing in 
the fetus is characterized by regeneration of an organized 
dermis with normal appendages and by a relative lack of 
inflammation. Another line of evidence showing that it 
is indeed fetal skin cells themselves that are responsible 
for scarfree tissue repair is that the in utero environment 
does not seem to be essential nor sufficient for scarless 
fetal repair. Fetal skin outside the warm, sterile, growth 
factor-rich amniotic environment has been shown to be 
very efficient in scarless and rapid healing. This has been 
demonstrated with an opossum model as this marsupial 
is born fetal like, both physiologically and anatomically, 
and remains attached to the mother’s nipple for 4–5 weeks 
 [18] . Despite their extrauterine location, wounds in early-
pouch young re-epithelialize very quickly, synthesize 
collagen and heal without scar. In contrast, wounds in 
older-pouch young heal more slowly and with scar for-
mation. In this same line, human fetal skin transplanted 
subcutaneously to an immunoincompetent mouse re-
tained its developmental characteristics and healed with-
out scar along with restoration of hair follicules and re-
ticular collagen arrangement  [20] . As the regenerative ca-
pabilities of human fetal skin were not disrupted by an 
adult extrauterine wound environment or contact with 
adult mouse blood, the scarless capacities appear to be 
intrinsic to the fetal tissue itself, and the fetal dermal cells 
themselves are most likely the main effectors of scarless 
healing in fetal tissue.
 Fetal fibroblasts have the capacity to deposit wound 
collagen in a fine, highly organized pattern that is indis-
tinguishable from the surrounding uninjured dermal 
collagen. The fibroblasts themselves are the principal 
source of collagen which is the major component of ECM 
 [21] .
 Differences between scarring and scarless collagen ar-
chitecture may be partially explained by differences in 
collagen profiles between fetal and adult fibroblasts. In 
human fetal skin, collagen type III comprises 30–60% of 
the total, in adult skin 10–20%. Collagen type III fibers 
are smaller and finer than type I fibers, whereby the high-
er portion of type III fibers may allow a more reticular 
pattern of fiber deposition. With increasing age of gesta-
tion, the relative collagen ratios in fetal skin approach 
that of adults, correlating with the transition from scar-
less repair to scar formation. In addition to collagen, a 
different profile of glycosaminoglycan and protoglycan 
synthesis can be observed in fetal ECM. Early gestational 
fetal skin is rich in hyaluronic acid (a glycosaminoglycan) 
and fibromodulin (a protoglycan), but poor in decorin 
(protoglycan) compared to matured fetal skin or adult 
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skin  [20] . Fetal fibroblasts can simultaneously proliferate 
and synthesize collagen, and the migration of these cells 
into a wound is thought to be involved in replacing the 
ECM in tissue repair either directly or indirectly by stim-
ulating host tissue. Migration is an important fibroblast 
response following tissue injury and is crucial to the re-
pair process. Fetal fibroblasts possess more rapid intrin-
sic rates of migration than those seen in adult skin fibro-
blasts.
 Scarless fetal wounds heal with little inflammation, 
and the onset of scarring during fetal repair correlates 
with the presence of an acute inflammatory infiltrate  [22] . 
In addition, introduction of inflammation into normally 
scarless-healing wounds results in increases in collagen 
deposition and scarring. This suggests an important func-
tion of inflammation during scar formation. As the im-
mune system develops and its resulting inflammatory re-
sponse increases, scar formation occurs at the repair site. 
Synthesis and remodeling of the ECM by wound fibro-
blasts is likely the major determinant of dermal architec-
ture after repair. Differences between scarring and scar-
less collagen architecture may be partly explained by phe-
notypic differences between adult and fetal fibroblasts.
 Molecular Analysis of Scarless Wound Healing 
 Molecular analysis of wound healing has largely been 
devoted to cytokines and most particularly those of the 
transforming growth factor (TGF) family and their role 
in manipulating cutaneous wound healing and scar for-
mation. It has been suggested that scarless wound healing 
in fetal skin at early gestation is a result of the unique cy-
tokine or growth factor profile. Of these, TGF-  has been 
most widely studied as it is implicated in the transition 
between scarless healing and repair with scar formation. 
In this process, growth factors’ main functions are to 
control cell proliferation and differentiation and to stim-
ulate the synthesis of ECM such as collagen. Three high-
ly homologous TGF-  isoforms are known in humans: 
  1,   2 and   3. Each form has been found by immunohis-
tochemistry in unwounded fetal skin. However, low lev-
els of TGF-  1 and high levels of TGF-  3 are expressed at 
gestational ages associated with scarless repair. In addi-
tion, it appears that the relative proportion of TGF-  iso-
forms, and not the absolute concentration of any one iso-
form, determines the wound repair outcome  [23, 24] . 
 Exogenous application of TGF-  1 to normally scar-
less fetal wounds resulted in scar formation with an adult-
like inflammatory response observed. The profibrotic 
nature of TGF-  1, and possibly TGF-  2, was confirmed 
in wounds of adult rats, since neutralizing TGF-  1 and 
TGF-  2 with antibodies partially reduced the amount of 
scarring. TGF-  1 stimulates collagen I production, which 
is the predominant collagen type in adult skin. On the 
other hand, supplementation with TGF-  3 reduced scar-
ring and inflammation in adult wounds confirming its 
potential antifibrotic properties. The fact that scarless fe-
tal wounds heal with little inflammation and that the on-
set of scarring during fetal repair correlates with the pres-
ence of an acute inflammatory infiltrate, may be related 
to the pronounced anti-inflammatory properties of
TGF-  3.
 However, TGF-  1- and TGF-  2-neutralizing anti-
bodies do not entirely prevent scarring in the adult, and 
other studies question the efficacy of TGF-  3 in wound 
healing  [25–27] . This suggests that factors other than 
TGF-  may also be important in scarless repair. As 
wound healing is very complex, there are certainly many 
other molecules within the TGF-  superfamily which 
could have a role. For instance, ECM constituents fibro-
modulin or decorin, which are expressed as a function of 
gestational age in fetal skin, are known to modulate TGF-
  activity. Bone morphogenic protein (BMP) family of 
genes and their receptors are among those in the TGF-  
superfamily genes and have also been strongly associated 
with cutaneous wound healing and scarless wound heal-
ing in the fetus. More recent studies have shown evidence 
for the importance of angiogenesis and nerve formation 
in wound repair involving pleiotropin (PTN) and mid-
kine (MK), two members of the  Ptn/Mk developmental 
gene family which are also in the TGF-  superfamily 
 [28–30] .
 By selecting families of genes that have been reported 
to be implicated in wound repair and particularly for scar-
less fetal wound healing, including the TGF-  superfam-
ily, ECM and nerve/angiogenesis growth factors, we have 
analyzed differences in their expression between fetal 
skin and foreskin cells and the same passages. Of the 5 
TGF-  superfamily genes analyzed by real-time RT-PCR, 
3 were found to be significantly different with 6-fold up-
regulation for TGF-  2 and 3.8-fold for BMP-6 in fetal 
cells, whereas GDF-10 was 11.8-fold downregulated. For 
nerve growth factors, MK was 36.4-fold downregulated in 
fetal cells and PTN was 4.76-fold upregulated ( table 1 ).
 By studying the differences between fetal skin cells 
and other cell types already therapeutically used in hu-
mans since several years, it may be possible to identify 
important markers in gene families known to have an 
impact in this complex process, and these differences in 
gene expression could contribute to the degree of effi-
ciency seen in clinical use with these cells.
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 Cell Choice in Out-Scaling for Tissue Engineering 
 Fetal cells offer many advantages over other cell choic-
es for tissue engineering and these are summarized in 
 table 2 . Fetal skin cells, at the age and passages used for 
cellular therapy in biological bandages, have been shown 
to be efficient in total skin repair for burns and wounds. 
 Technical Requirements 
 Fetal skin cells offer an ideal solution for effective and 
safe tissue engineering for wounds of all nature for sev-
eral reasons, including (1) cell expansion capacity from 
one organ donation, (2) minimal cell growth require-
ments, (3) adaptation to biomaterials for delivery and (4) 
resistance to oxidative stress. Firstly, fetal skin cells have 
extensive expansion possibilities as it requires only one 
organ donation (1–4 cm 2 tissue) to create enough frozen 
cells to produce a bank capable of making over 270 mil-
lion fetal skin constructs (9  ! 12 cm, TissueFleece; Bax-
ter). Secondly, cell culture requirements are minimal 
compared to stem or mesenchymal cell types. As the fetal 
skin cells are already differentiated and do not need to be 
directed or altered, the vast numbers of additional growth 
factors normally necessary are not needed for cell culture 
and expansion. Similar procedures that exist industrially 
for vaccine preparation can be implemented for up-scal-
ing of fetal cells. Indeed, the polio vaccine was developed 
with the use of fetal kidney cells already in 1950. For cell 
Table 1. Regulation of genes in cells from fetal skin versus foreskin and their biological process
Gene Accession Regulation in
fetal skin vs.
foreskin, n-fold
difference
Biological process in skin or other tissue (DAVID)
TGF-1 NM_000660 1.4 down cell-cell signaling
inflammatory response
anti-apoptosis
regulation of progression through cell cycle
development and organ morphogenesis
cell proliferation and differentiation
TGF-2 NM_003238 6.05 up cell death
angiogenesis
embryonic development
cell proliferation and differentiation
mesoderm formation
neutrophil chemotaxis 
wound healing
hair follicle development and morphogenesis
dopamine biosynthesis
negative regulation of keratinocyte differentiation
somatic stem cell division
cellular morphogenesis
regulation of progression through cell cycle
TGF-3 NM_003239 0.5 up signal transduction
cell-cell signaling
cell growth and proliferation
regulation of progression through cell cycle
organ morphogenesis
collagen production
BMP-6 NM_001718 3.8 up cell differentiation
growth
development
skeletal and cartilage development
bone formation
skin homeostasis
GDF-10 NM_004962 11.8 down TGF- receptor signaling pathway skeletal development
bone formation
MDK NM_002391 36.4 down signal transduction
cell-cell signaling
cell proliferation 
cell differentiation
regulation of progression through cell cycle
nervous system development
response to wounding
development
PTN NM_002825 4.76 up nervous system development
cell proliferation
angiogenesis
regulation of progression through cell cycle
signaling pathway
DPT NM_001937 1.5 down cell adhesion
ECM
matrix assembly
LAMb1 NM_005573 1.3 down ECM cell adhesion
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banking, careful selection of a donor and an extensive 
screening of both the donor and cultured cells to avoid 
transmissible viral, fungal or bacterial disease provide a 
safe and secure utilization of fetal cells for therapeutic us-
age. 
 In addition, fetal cells, unlike neonatal, young or adult 
cells, adapt particularly well to biomaterials, allowing ef-
ficient and simple delivery to the patient. In our labora-
tory and in others, it has been shown that cells from do-
nors (neonatal to adult) are not capable of efficient inte-
gration into various biomaterials and some biomaterials 
are in fact toxic to the cell. Ng et al.  [31] and Monjovent 
et al.  [32] have emphasized that physical characteristics 
of scaffolds such as porosity and mechanical stability are 
important for withstanding cell contraction forces and 
assuring a homogenous distribution of cells throughout 
the scaffold. It is true that the scaffold is very important 
for tissue engineering, but the cell type is most probably 
the limiting factor. We have seen that fetal cells adapt well 
to various biomaterials  [13, 32] . For processing of a final 
product for clinical delivery, both the homologous distri-
bution and the rapidity of development of the final prod-
uct are major significant advantages. When long culture 
periods are necessary, as for autologous grafting or for the 
skin products commercially available to date, there is a 
nonnegligible increased risk for contamination. It is also 
important to have a process that is consistent and easily 
repeatable. By developing consistent cell banks with fetal 
cells, many of the risk factors can be eliminated for bring-
ing safe and effective human cell-based therapies to the 
bedside.
 Along with their rapid growth, simple cell culture re-
quirements and ease of association with bioscaffolds, fe-
tal cells have been shown to be highly resistant to oxida-
tive and physical stresses, making them highly suitable 
for hostile wound environments  [13] . These cells may be 
more efficient in scavenging potential damaging free 
radical intermediates or perhaps they are more efficient 
in processing and repairing oxidative damage to critical 
cellular targets. Fetal cells can survive at lower oxygen 
tensions than adult cells and possess more resistance to 
ischemia during in vitro manipulations. This along with 
the lack of strong intercellular adhesion in fetal cells ren-
der them more resistant to refrigeration and cryopreser-
vation techniques than adult cells  [13] . Indeed, in our lab-
oratory, we see a recovery of frozen cells between 95 and 
99%, whereas the rates of recovery of young and adult 
cells are easily 10–15% lower.
 Therapeutic Requirements 
 Importantly, three-dimensional cutaneous tissue al-
lografts developed from fetal skin banks show for the first 
time that a biological skin substitute is capable of provid-
ing a very high quality of skin repair/replacement in a 
short period of time with no additional grafting tech-
nique necessary and no immunological or pro-inflam-
matory reaction seen in any of the clinical studies  [12, 13, 
32] . More recently, it has been shown that, when grafts are 
prepared with a majority of dermal fibroblasts in propor-
tion to keratinocytes, the stimulation of healing is much 
greater  [6] . 
 The need for dermal components to avoid secondary 
scar contraction and to assist in a good esthetic and me-
chanical result of tissue repair has been well accepted 
 [33] .
 It is thus perhaps related to the age of the fetal dermal 
fibroblasts (14 weeks of gestation) that are used alone, as 
they are capable of providing total wound closure with-
out any secondary grafting technique necessary.
Table 2. Requirements for an ideal cell source for skin tissue engineering applications
Technical requirements Therapeutical requirements
collection culture expansion storage skin
formation
no immunologi-
cal reaction
no pro-inflamma-
tory reaction
Bone marrow cells + + NA NA NA + + + + +
Mesenchymal stem cells + + + + + + + + – + + + + + +
Adult stem cells + + + + + + + + + + +
Fetal skin cells + + + + + + + + + + + + + + + + + + + +
A high compliance to the requirement is denoted by + + +, while NA means nonadequate.
The immunological reaction refers to the use of cells in an allotransplantation.
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 Ethical Aspects of Working with Human Fetal Cells 
 Although there is high medical support for developing 
cellular-based therapies to reach as many patients as pos-
sible, there exists a governing political controversy. Sci-
entists and medical doctors have used fetal tissue since 
the 1930s as a means to understand cell biology and as an 
essential tool in the development of vaccines. The 1954 
Nobel Prize for Medicine was awarded to immunologists 
who developed the polio vaccine using cultures of human 
fetal kidney cells. The political environment changed 
drastically in 1988 when scientists began using fresh fetal 
tissue and cells for transplantation into patients with Par-
kinson’s disease. Unfortunately, the Reagan administra-
tion (US government) declared a moratorium on all fed-
eral funding for fetal tissue research. Advances in fetal 
cell research were then left only to the private sector 
where there is no medical peer review of adapted thera-
pies. Indeed, if research on whole-cell bioprocessing of 
many fetal tissues could have continued, there certainly 
would have been advances in the amount of tissue neces-
sary for developing efficient therapies (such as with fetal 
skin where only one organ donation is necessary to allow 
for cellular expansion to develop over 270 million fetal 
cell constructs). In Switzerland and most other countries, 
fetal skin is considered as an organ donation by law. This 
process is highly regulated, including federal approval for 
tissue biopsy, stocking and transplantation as well as eth-
ics committee approval of the procedure and all informa-
tion for the donor. Even though termination of pregnan-
cy is legally allowed, there will always be strong oppo-
nents, meaning that the laws and practices remain patient 
centered (conditions which permit to end an unwanted 
pregnancy in the best possible way and without unneces-
sary suffering; www.fiapac.org/e/Links1.html). 
 Processing of a Fetal Cell Bank and
Tissue-Engineered Product 
 Specific cell culture from biopsy material has been 
previously described elsewhere  [13, 14] and is summa-
rized in  figure 1 . Briefly, fetal skin biopsies were cleaned 
of adherent tissue, washed 3 times for 15 min each in 
phosphate-buffered saline (NaCl 6.80 g/l, Na 2 HPO 4 
1.48g/l, KH 2 PO 4 0.43g/l), dissected and put into culture 
in tissue culture-grade plates (60 cm; Falcon). Once the 
adherent cells reached 80% confluence, they were tryp-
sinized (EDTA and trypsin solution; Gibco), amplified 
and ampoules of cells in 1 ml of freezing medium (50% 
DMEM, 40% FCS, 10% DMSO) were stored in liquid ni-
trogen. Cell banks were stored in the vapor phase of 
alarm-fitted (to assure sufficient liquid nitrogen) liquid 
nitrogen storage vessels (Carbagas) rather than in the liq-
uid phase, and portions of each cell bank were split be-
tween different vessels in separate locations for security. 
Although very extensive data tracking is essential for 
good manufacturing practice records, for our laboratory 
cell banks, we have prepared a certificate of analysis for 
each cell bank, giving its designation, number of am-
poules prepared, date, tests performed, specification and 
results. Ampoules were labeled with the cell bank code 
and each ampoule was individually numbered. Logbooks 
were used to record all ampoule movements including 
the initial deposit of the cell bank and also each time an 
ampoule was removed whether for testing or for experi-
mental purposes. These changes were signed and dated 
in the cell bank logbook. 
 The master cell bank (MCB) of 1 cell line destined for 
clinical use was characterized and extensively tested in 
the good manufacturing practice facilities of Bioreliance 
in Glasgow, UK, to demonstrate the absence of viruses. 
Testing requirements were based on those required for 
human diploid cells used for vaccine production and for 
cell substrates used for biotechnological products. Al-
though the donor is obviously human, isoenzyme test-
ing to show Caucasian human origin is necessary for 
documentation. Other tests were sterility, mycoplasma 
and retroviral reverse transcriptase activity (FPERT as-
say). Examinations for viruses, virus-like particles, my-
coplasmas, fungi, yeasts and bacteria were done with a 
minimum of 200 cell profile with quantitative transmis-
sion electron microscopy. In vitro testing of picornavi-
rus, orthomyxovirus, paramyxovirus, herpesvirus, ad-
enovirus and reovirus was accomplished with several 
control cell lines. In vivo virus testing was completed 
using suckling mice, adult mice, guinea pigs and em-
bryonated eggs. Human virus detection was screened 
using Q-PCR for the following viruses: HepB, HepC, 
HIV-1, HIV-2, HTLV-1, HTLV-2, HHV-6, HHV-7, HHV-
8, EBV, hCMV and SV40. B19 parovirus was also screened 
with Q-PCR. Safety testing of the working cell bank 
(WCB) for preclinical and research projects can then be 
somewhat limited compared to the MCB safety testing, 
since each MCB ampoule results in a full WCB. Safety 
testing for laboratory research-developed cell banks 
needs to be continually controlled for mycoplasma and 
bacterial contamination.
 Regarding the use of the cells for preclinical trials only, 
it will be particularly important to ensure consistency of 
growth of the cells and consistency of the harvest ob-
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tained. High consistency in fetal cell banking can be 
achieved due to the minimum nutrient requirements of 
fetal cell cultures. In contrast with mesenchymal stem 
cells, fetal cells do not require feeder layers for growth nor 
growth factors for differentiation. For skin tissue-engi-
neered products (TEP), many products to date use a pool 
of multiple donors for a batch of cells. The differences 
between donors would not be as important, since many 
donors could be used. There is low heterogeneity between 
fetal donors for skin cell banks established in the same 
manner (large-scale expansion). Cell counts, protein de-
termination and gene expression analysis are useful tools 
to assess the consistency of the cell banks when there is 
only one unique donor for skin TEP. Limits of variation 
for these assays specific for each cell type will need to be 
established internally to define the consistency of the 
process. For therapeutic use, fetal cells can be used up to 
two thirds of their life span in an out-scaling process. 
These overall criteria would be sufficient for limited pre-
clinical trials in a university situation. However, if the 
goal is to develop a product used on a large-scale or a mul-
ticentric basis, assessment of the cell-derived product 
should not be restricted to description parameters such 
as protein concentration, but should include a functional 
assay. Furthermore, the activity of the final product is 
likely to be due to synergistic effects of multiple proteins, 
which cannot be assessed by individual protein concen-
tration or activity.
1 organ donation
(skin 2–4 cm2) Cell culture
Cell expansion and
cell bank creation 
Construct engineering
Cells from WCB
Absence of biopsy
for the patient Rapid cell growth Quality control simplified
Simple preparation and application No staples, glue or sutures necessary 
48 h
Cell bank preparation and stockage
Tissue engineering and patient treatment
First cover burn patients
construct molds over wounds 
Cryopreservation stockage
–165° C
(~2,400 Vials, MCB)
 Fig. 1. Processing of a fetal cell bank and TEP. One fetal skin donation of approximately 12 weeks of gestation 
can be expanded in tissue culture to develop MCB and WCB. Cells from frozen WCB can be used for direct 
seeding onto collagen sponges for rapid delivery to patients (approx. 48 h). Over 270 million biological ban-
dages can be developed from 1 MCB and provide first cover of burns in thousands of patients. 
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Day 7
a b
c d
Day 7Day 1
Day 20
 Fig. 3. Clinical use of skin biological ban-
dages (TEP). Fetal skin construct applica-
tion. Second- and third-degree burn on 
the hand (a) with escarotomy performed at 
7 days (b) and fetal skin construct applica-
tion enveloping all digits (c). Total closure 
and repigmentation seen at 20 days after 
therapy (d). Scale bar = 1 cm. 
–80°C 
3 months
27 months
 Fig. 2. Stability of skin biological bandages (TEP). Scaffolds [fetal 
cells were seeded at a density of 2,500 cells/cm 2 on equine collagen 
scaffolds (Baxter Tissue Fleece  )] were cultivated a few days and 
then conserved at different temperatures to observe the stability 
of the construct and the cellular viability for 1–4 weeks (24, 4, –20 
and –80 ° C) and up to 2 years for frozen constructs. Cells could 
be easily grown from constructs at all temperatures for up to 1 
month and from frozen constructs at –80 ° C for up to 27 months 
(cell morphology 100 ! ). 
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 As we have seen, each element necessary to produce a 
successful TEP needs to be verified for safety and consis-
tency in the development. Cell choice for TEP is of utmost 
importance, and progress to assure the consistency will 
be necessary before allowing preclinical trials. Using only 
one fetal organ donation, it is possible to develop exten-
sive MCB and WCB. Fetal cells, as an already differenti-
ated lineage, need low nutritional requirements (that is, 
no feeder layers or external growth factors) to establish a 
fully defined consistent cell bank and can easily be as-
sessed for safety assuring an interesting cell choice for 
TEP.
 WCB can be used to develop consistent TEP as depict-
ed in  figure 1 . Cells from 1 vial of frozen WCB can be 
directly seeded on 9  ! 12 cm collagen sponge. These can 
be used directly on the patient after 48 h of incubation at 
37 ° C and 5% CO 2 . Many constructs can be prepared in a 
minimal amount of time, which could be used in the hos-
pital’s burn center. These biological constructs have been 
shown to be highly stable. Positive cell growth was seen 
when scaffolds were seeded with fetal cells at a density of 
2,500 cells/cm 2 on equine collagen scaffolds (Baxter Tis-
sue Fleece  ), cultivated a few days and then conserved at 
different temperatures to observe the stability of the con-
Cultured fetal skin cells – male donor
Skin biopsy at 6 months after treatment – female recipient
Epidermis
Chr. X
Chr. XDAPI 
Chr. Y
Chr. Y
Chr. XDAPI Chr. Y
Dermis
 Fig. 4. Fluorescence in situ hybridization (FISH) for presence of 
fetal cells. As the fetal cells came from a male donor, the FISH 
technique was used to observe if there was any incorporation into 
1 female recipient 6 months after therapy. A full-thickness biopsy 
was taken in the area that was burned at third degree and where 
a total of 5 fetal constructs were applied. The biopsy represented 
approximately 2,500 epidermal cells and 3,500 dermal cells. The 
whole surface was screened by FISH, with no cells found to have 
a Y chromosome. For comparison, a total of 200 cells were ana-
lyzed in the epidermis and 200 cells in the dermis to verify female 
karyotype (cell morphology 100 ! ). In the epidermis, 79% of the 
cells contained 1 or 2 X chromosome-specific spots, whereas in 
the dermis, this proportion reached 83%. On average, the number 
of X spots per cell nucleus was 1.17, which is consistent with a dip-
loid pattern (XX karyotype) on 4-  m thick histologic sections, 
where most cell nuclei are in fact truncated. 
 Applegate /Scaletta /Hirt-Burri /Raffoul /
Pioletti 
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struct and the cellular viability for 1–4 weeks (24, 4, –20 
and –80 ° C) and up to 2 years for frozen constructs. Cells 
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 TEP for Clinical Use 
 Constructs can be prepared from off-the-shelf WCB 
frozen vials of fetal skin cells by incubation for 48 h before 
delivery to the patient. These biological constructs can be 
easily made in large numbers, allowing immediate use for 
first cover of burns and wounds. Up until now, cadaver 
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the-shelf would therefore be an advantage in burn man-
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 In a study including 8 pediatric burn patients, time to 
healing for the burns was 14.3  8 9.15 days after the first 
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pain relief was noticed following application of the first 
construct. This was particularly striking in small chil-
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 This wound closure does not seem to be associated 
with an actual grafting of the fetal cells into the patient. 
Biopsies taken on third-degree burn sites at 6 months af-
ter treatment were analyzed using the FISH technique 
and show that donor fetal skin cells were not incorpo-
rated into the receiver skin ( fig. 4 ).
 Conclusions 
 Overall, it is important to have a safe and effective 
means for enhancing the healing of wounds. Processing 
of cells and their delivery systems need to be easy, as does 
the verification of consistency of both the cells and the 
final product. Fetal skin cells provide an interesting al-
ternative to autologous cells, stem cells, mesenchymal 
cells and neonatal foreskin cells (the most frequently used 
cell types to date), since they fulfill these requirements. 
 Even under the most optimal conditions, adult cuta-
neous repair results in scar. Thus, fetal skin represents 
the ideal paradigm of all tissue repair due to its inherent 
ability to repair through regeneration rather than scar. 
More importantly, its clinical use has been shown to al-
leviate painful autografting and prolonged treatment 
regimens and to be one step closer to ‘perfect skin re-
pair’.
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